SCHEMBL29988703

SCHEMBL29988703

O=C(Oc1cccnc1)N1CCNCC1

nearest known ligand 0.52

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 1/20 0.52
MKNK2 Q9HBH9 1/20 0.52
ALDH1A1 P00352 3/20 0.46
MGLL Q99685 1/20 0.46
FNTA P49354 3/20 0.45
FNTB P49356 3/20 0.45
KMT2A Q03164 2/20 0.43
ALOX15 P16050 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
TSHR P16473 1/20 0.43
MAPK1 P28482 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HIF1A Q16665 1/20 0.43
POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12271108 1.00 MKNK1 (0.52) MKNK1MKNK2ALDH1A1MGLLFNTA
Hydrochloric Acid SCHEMBL1532934 0.99 MKNK1 (0.51) MKNK1MKNK2ALDH1A1MGLLFNTA
SCHEMBL30488786 0.86 ALDH1A1 (0.54) ALDH1A1MGLLFNTAFNTBKMT2A
SCHEMBL31596236 0.86 ALDH1A1 (0.54) ALDH1A1MGLLFNTAFNTBKMT2A
SCHEMBL30541505 0.86 ALDH1A1 (0.59) ALDH1A1FNTAFNTBKMT2ATSHR
SCHEMBL27722718 0.85 ALDH1A1 (0.62) ALDH1A1FNTAFNTBKMT2ATSHR
SCHEMBL1652022 0.84 FNTA (0.46) ALDH1A1MGLLFNTAFNTBKMT2A
Hydrochloric Acid SCHEMBL1532689 0.84 ALDH1A1 (0.60) ALDH1A1KMT2AALOX15TSHRSMN1; SMN2
SCHEMBL3484927 0.82 FNTA (0.50) MGLLFNTAFNTBKMT2A
SCHEMBL28864238 0.81 ALDH1A1 (0.51) ALDH1A1KMT2AALOX15CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026098683-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE THEREOF 盛睿泽华医药科技(苏州)有限公司 2026-05-15 WO disclosed
WO-2024227104-A1 BIFUNCTIONAL COMPOUNDS FOR DEGRADING BRAF VIA UBIQUITIN PROTEOSOME PATHWAY NURIX THERAPEUTICS, INC. (US) 2024-10-31 WO disclosed
EP-4313987-A2 PROCESS FOR THE PREPARATION OF RIBOCICLIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF KRKA, d.d., Novo mesto (SI) 2024-02-07 EP disclosed
WO-2022207788-A2 PROCESS FOR THE PREPARATION OF RIBOCICLIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF KRKA, D.D., NOVO MESTO (SI) 2022-10-06 WO disclosed